Pediatrix Medical Group (NYSE:MD) Upgraded at StockNews.com

StockNews.com upgraded shares of Pediatrix Medical Group (NYSE:MD) from a hold rating to a buy rating in a report released on Wednesday morning.

Several other equities analysts have also issued reports on MD. Deutsche Bank Aktiengesellschaft lifted their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Mizuho boosted their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. Truist Financial increased their target price on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. UBS Group upped their price objective on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Jefferies Financial Group raised their target price on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $16.10.

Pediatrix Medical Group Stock Down 0.7 %

Shares of NYSE MD opened at $14.07 on Wednesday. The stock has a market capitalization of $1.21 billion, a P/E ratio of -4.60, a PEG ratio of 2.02 and a beta of 1.57. The stock’s fifty day moving average is $13.96 and its 200 day moving average is $10.73. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $16.41. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The company had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.29 EPS. Sell-side analysts forecast that Pediatrix Medical Group will post 1.26 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the sale, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. The trade was a 16.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. The trade was a 5.63 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Rubric Capital Management LP increased its position in shares of Pediatrix Medical Group by 797.0% during the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after buying an additional 7,241,400 shares during the period. Dana Investment Advisors Inc. grew its holdings in Pediatrix Medical Group by 80.3% during the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after acquiring an additional 455,785 shares during the period. Weiss Asset Management LP raised its position in shares of Pediatrix Medical Group by 50.5% in the 3rd quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock worth $10,580,000 after acquiring an additional 306,143 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in shares of Pediatrix Medical Group by 639.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock valued at $2,192,000 after purchasing an additional 251,072 shares during the period. Finally, ClariVest Asset Management LLC bought a new stake in shares of Pediatrix Medical Group during the 2nd quarter valued at about $1,721,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.